GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurizon Therapeutics Ltd (FRA:ECQ0) » Definitions » EBITDA Margin %

Neurizon Therapeutics (FRA:ECQ0) EBITDA Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Neurizon Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Neurizon Therapeutics's EBITDA for the six months ended in Dec. 2024 was €-5.47 Mil. Neurizon Therapeutics's Revenue for the six months ended in Dec. 2024 was €0.00 Mil. Therefore, Neurizon Therapeutics's EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.


Neurizon Therapeutics EBITDA Margin % Historical Data

The historical data trend for Neurizon Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurizon Therapeutics EBITDA Margin % Chart

Neurizon Therapeutics Annual Data
Trend Jun01 Jun02 Jun03 Jun04 Jun05 Jun24
EBITDA Margin %
Get a 7-Day Free Trial -424.50 -363.84 -665.00 -100.10 -

Neurizon Therapeutics Semi-Annual Data
Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Jun24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -60.43 9.59 - - -

Competitive Comparison of Neurizon Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Neurizon Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurizon Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurizon Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Neurizon Therapeutics's EBITDA Margin % falls into.


;
;

Neurizon Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Neurizon Therapeutics's EBITDA Margin % for the fiscal year that ended in Jun. 2005 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2005 )/Revenue (A: Jun. 2005 )
=-2.042/2.04
=-100.10 %

Neurizon Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-5.465/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neurizon Therapeutics  (FRA:ECQ0) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Neurizon Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Neurizon Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurizon Therapeutics Business Description

Traded in Other Exchanges
Address
96-100 Albert Road, Level 4, South Melbourne, Melbourne, VIC, AUS, 3205
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).

Neurizon Therapeutics Headlines

No Headlines